Adjuvant Therapy Approaches in Melanoma Management

Adjuvant therapy in melanoma seeks to eliminate micrometastatic disease following surgical resection, thereby reducing the risk of recurrence and improving long-term survival. Modern approaches are dominated by two complementary strategies: immune-checkpoint blockade and targeted inhibition of oncogenic pathways. Immune-checkpoint inhibitors directed against CTLA-4 or PD-1 receptors have transformed outcomes in high-risk stage II and III disease by reactivating antitumour immunity. Parallel advances in targeted therapy focus on patients whose tumours harbour activating mutations in BRAF, typically treated with combinations of BRAF and MEK inhibitors. Selection of adjuvant regimens is informed by clinicopathological risk factors, mutational profiling and emerging biomarkers, with recurrence-free survival (RFS) and distant metastasis-free survival (DMFS) as key end points. Toxicity profiles vary, with immune-related adverse events and targeted-therapy–associated pyrexia or cutaneous effects requiring careful management. Ongoing research seeks to refine patient stratification, explore novel combinations and integrate neoadjuvant approaches to further diminish recurrence rates and optimise quality of life.

Research from Nature Portfolio

Recent studies have demonstrated the efficacy of adjuvant PD-1 blockade in earlier stages of melanoma. In a randomised phase III trial involving patients with resected stage IIB/C disease, adjuvant nivolumab administered every four weeks for one year nearly halved the risk of recurrence compared with observation, achieving 12-month RFS rates close to 90 % versus 80 %. Distant metastasis-free survival was likewise improved, and the regimen was generally well tolerated, with grade 3–4 adverse events occurring in around 10 % of recipients. These findings have extended the clinical indication for PD-1 inhibitors into cohorts previously deemed at moderate risk, underscoring the potential to forestall metastatic spread even in earlier disease stages.

Adjuvant Therapy Approaches in Melanoma Management publication trend

The graph below shows the total number of articles in adjuvant therapy approaches in melanoma management across all publications each year (not limited to Nature Index journals).

Technical terms

Adjuvant therapy: Treatment given after primary surgery to eliminate residual disease and reduce recurrence risk.

Immune-checkpoint inhibitor (ICI): An antibody that blocks regulatory receptors (e.g., CTLA-4, PD-1) on T cells to enhance antitumour immunity.

Recurrence-free survival (RFS): Time from treatment initiation to the first detection of tumour recurrence.

Distant metastasis-free survival (DMFS): Interval until the appearance of metastases at sites remote from the primary tumour.

BRAF/MEK inhibitors: Targeted agents that inhibit the MAPK pathway in tumours bearing BRAF V600 mutations.

References

1. Adjuvant nivolumab in resected stage IIB/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial. Nature Medicine (2023).
2. Adjuvant Nivolumab Versus Ipilimumab in Resected Stage III/IV Melanoma: 5-Year Efficacy and Biomarker Results From CheckMate 238. Clinical Cancer Research (2023).
3. Management of early melanoma recurrence despite adjuvant anti-PD-1 antibody therapy☆. Annals of Oncology (2020).
4. Melanoma recurrence patterns and management after adjuvant targeted therapy: a multicentre analysis. British Journal of Cancer (2020).